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histologic fibrosis. Advances in therapy with direct acting antivirals have led to 
improvements in treatment success. The objective of this study was to assess if 
it is now cost-effective to treat all CH-C genotype 1 patients regardless  
of histologic fibrosis stage. METHODS: A decision analytic Markov model 
simulating patients until death was used to compare two strategies for treating 
CH-C genotype 1: Triple therapy with biopsy (TT) or treat all (TTA). For TT, 
patients with moderate or advanced fibrosis were treated; others were biopsied 
every 5 years until age 70. Triple therapy consisted of telaprevir for 12 weeks, 
along with double-therapy (pegylated-interferon and ribavirin) for 24 or 48 weeks 
depending on response. The reference case was a treatment-naïve 50-year-old. 
Parameters were taken from the literature, Medicare fee schedule and  
drug acquisition cost. Effectiveness was measured in quality-adjusted life 
years(QALYs), and disease progression. Strategies were compared on the basis of 
cost, effectiveness and the incremental cost-effectiveness ratio (ICER, in $/QALY). 
Cost and effectiveness were discounted at 3% annually. RESULTS: For TT, 58% 
were treated initially and 25% were treated later. TTA led to less disease 
progression: Decompensated cirrhosis (11.8% vs. 13.4%), liver cancer (10.5% vs. 
12.0%), and liver transplant (4.6% vs. 5.2%). TTA was more expensive, $103,135 vs. 
$90,904, but more effective, 17.195 vs. 16.383 QALYs. TTA was very cost- 
effective with an incremental cost-effectiveness ratio of just $15,063/QALY. 
CONCLUSIONS: The recommendation to treat CH-C genotype 1 patients  
with moderate and advanced fibrosis, and monitor those with mild fibrosis, 
must be reassessed with increasingly more effective anti-HCV therapy.  
Treating everyone may be even more cost-effective for newer, more  
effective treatments with less side effects and shorter regimens (e.g. oral agents 
only).  
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OBJECTIVES: Current influenza vaccination practice using trivalent inactivated 
vaccine (TIV) and trivalent live attenuated influenza vaccine (LAIV) covers only 
one of two commonly circulating influenza B lineages; mismatch and co-
circulation are frequent and unpredictable. We evaluated the health outcomes 
and cost-effectiveness of universal vaccination with QIV compared with current 
vaccination practice. METHODS: We used a 1-year decision-tree from a societal 
perspective, including influenza-associated productivity losses and death. US 
Population was stratified to model age-specific (< 5, 5-17, 18-49, 50-64, and 65+) 
vaccination coverage, vaccine efficacy and risks of influenza complications. 
Rates of influenza, health care utilization, disease-related costs, and survival 
were estimated from published data where possible. Annual cases, lifetime costs 
(2011 USD) and quality adjusted life years (QALYs) lost were calculated and 
discounted (3% per annum) appropriately. We conducted one-way and 
probabilistic sensitivity analyses. RESULTS: Results suggest that vaccination 
with QIV instead of TIV/LAIV is expected to yield 77,817 fewer medically-
attended influenza cases, approximately 4,360 fewer related hospitalizations and 
868 fewer deaths per year. QIV vaccination is expected to result in approximately 
4,342 fewer QALYs lost compared with TIV/LAIV. The model projects QIV to  
be cost-effective at $50,000/QALY, excluding death-related productivity losses, 
avoiding double counting as death-related QALYs are included, at a price 
increment of 35% over the average weighted TIV price. The increase  
in vaccination costs ($385 million) is offset by a $411 million reduction in 
influenza-related treatment costs, comprising $142 million in direct medical 
costs (physician visits, antivirals, and outpatient and inpatient care) and $269 
million in direct non-medical cost savings. Results were robust in sensitivity 
analyses. CONCLUSIONS: Under the model assumptions, a strategy of 
vaccination with a quadrivalent influenza vaccine is expected to be a cost-
effective alternative to current practice, by reducing the costs as well as cases, 
hospitalizations and deaths associated with vaccine-mismatched influenza B 
disease.  
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OBJECTIVES: To adapt an existing and previously published economic (micro-
simulation model) in HIV (ARAMIS) to evaluate the cost-effectiveness of 
maraviroc (MVC) in the US in treatment naïve HIV-patients based on the MERIT 
(Maraviroc versus Efavirenz in Treatment-Naive Patients) study. METHODS: MVC 
was compared to efavirenz (EFV) in treatment naïve patients with CCR5-tropic 
HIV. Efficacy and safety data were based on the post hoc analysis in the MERIT 
study in patients rescreened with an Enhanced Sensitivity Trofile Assay (ESTA). 
ARAMIS-MVC is a microsimulation Markov model, has a lifetime analytic time 
horizon with a monthly cycle length. Health states are defined in terms of 
chronic and acute HIV/AIDS. Treatment algorithms were updated based on 
guidelines and expert opinion. Long-term non-AIDS diseases (Cardiovascular, 
hepatic and renal diseases and non-AIDS defining cancer) were included in the 
model to reflect the higher prevalence of these illnesses in the HIV population 
and depended on age, CD4-cell count and hepatic status. Costs included 
antiretroviral treatment costs, HIV care, testing, adverse event (gastrointestinal 
events, rash, neuropsychiatric adverse events) and non-AIDS disease costs, at 
the 2012 level. The cohort of the model used the population included in the 
MERIT study and 1,000,000 simulations were used for the model. RESULTS: The 
ARAMIS-MVC model indicates that MVC compared to EFV over a life time is 
associated with some additional quality-adjusted life years (QALY) (0.092 
difference) but with some additional total costs ($8,900 additional costs for MVC). 
The incremental cost effectiveness ratio for MVC compared to EFV is $96,000 per 
QALY gained. Life expectancy with MVC was slightly higher than EFV (2.7 
months difference). CONCLUSIONS: MVC is a cost-effective treatment option for 
CCR5 tropic treatment-naïve patients in the US considering a threshold of 
$100,000/QALY.  
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OBJECTIVES: Current guidelines for the treatment of acute bacterial skin and 
skin structure infections (ABSSSI) recommend treatment pathways based on the 
infection types and severity. However, few studies have attempted to establish 
the health care resource utilization and costs overall and in various treatment 
settings, e.g., ED visits, in-patient, outpatient visit and/or treatment (e.g. infusion 
center), and outpatient pharmacy, using real world data. METHODS: The medical 
and pharmacy administrative claims of adult ABSSSI subjects with continuous 
commercial or Medicare Advantage enrollment with Part D prescription drug 
coverage (MAPD) between 01 January 2009 and 31 December 2011 were extracted 
from a large national health plan affiliated with OptumInsight. Subjects were 
grouped based on their initiation of five MRSA-active antibiotics: linezolid, 
vancomycin, daptomycin, clindamycin, or tigecycline. Health care resource 
utilization and costs were assessed for each treatment group. RESULTS: After 
applying inclusion and exclusion criteria, 8,332 commercial and 4,218 MAPD were 
included in the study. The average age was 50 years for commercial enrollees 
and 69 years for MAPD enrollees. The Quan-Charlson comorbidity index varied 
among treatment groups and, a majority of the clindamycin treatment subjects 
had few or no comorbidities. The average ABSSSI-related total health care cost, 
per patient per month, was $18,290 including $7,261(39.7%) for inpatient cost, 
$825(4.5%) for ED visits, $2,447 (13.4%) for outpatient treatment/visits, 
$1233(6.7%) for pharmacy claims, $971(5.3%) for office visits, and $5553 (30.4%) 
for other medical cost. The costs overall and in various treatment settings varied 
by initial antibiotic choices and insurance plans. CONCLUSIONS: Inpatient 
treatment remains the largest component of total ABSSSI treatment cost. To 
minimize the burden on the health care system, there is an urgent need to 
develop new antibiotics that prevent or decrease the number of hospitalizations 
and reduce the length of inpatient stays.  
 
PIN82  
COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH 
CHRONIC HEPATITIS C (HCV) GENOTYPE 1  
Mernagh P1, Feng J1, Del Cuore M2 
1Optum, Sydney, Australia, 2Merck Sharp & Dohme (Australia), Sydney, Australia  
OBJECTIVES: Boceprevir is indicated for the treatment of chronic hepatitis C 
virus (HCV) genotype 1 in combination with peginterferon-alpha and ribavirin 
(PEGATRON). Boceprevir plus PEGATRON has been shown to significantly 
increase sustained virologic response (SVR) rates in naive and previously treated 
adults with chronic hepatitis C (CHC) genotype 1, compared to PEGATRON 
alone.This analysis is to determine the cost-effectiveness of PEGATRON with 
boceprevir compared to PEGATRON alone in treatment-naive and treatment-
experienced patients in Australia. METHODS: A semi-Markov model was 
constructed to capture the early stages of CHC and the possibility of SVR, as well 
as important downstream health states which impact on quality of life, survival 
and resource utilisation. Early stages of liver disease were defined by levels F0 to 
F3 of METAVIR scoring system. Advanced stages were defined as compensated 
cirrhosis, decompensated cirrhosis, and primary hepatocellular carcinoma. 
Patients who moved from a baseline fibrosis score of F0-F3 to SVR were assumed 
to be free of any further disease progression, remaining in a viral-negative state 
until death. Patients who moved from a baseline fibrosis score of F4 to SVR were 
assumed to retain some risk of liver complications due to pre-existing liver 
damage. Subjects who failed to achieve SVR were assumed to be at risk of 
disease progression until death. Costs and preference-based utility values varied 
by health state, and were aggregated over the patients’ lifetimes to calculate an 
incremental cost-utility ratio. RESULTS: The base case incremental cost-utility 
ratio was AU$38,712 per additional QALY in the treatment-naïve population, and 
AU$33,750 in the treatment-experienced population. The model was robust to 
variations in the SVR rate and model duration. CONCLUSIONS: The use of 
boceprevir for untreated chronic genotype 1 HCV is a cost-effective option for 
adult patients with CHC genotype 1.  
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OBJECTIVES: Current U.S. Department of Health and Human Services (DHHS) 
HIV treatment guidelines recommend that HIV patients initiate first-line 
antiretroviral therapy (ART) with one of four “preferred” regimens: 
efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC), ritonavir-boosted atazanavir + 
tenofovir/emtricitabine (ATV/r+TDF/FTC), ritonavir-boosted darunavir + 
tenofovir/emtricitabine (DRV/r+TDF/FTC), or raltegravir + tenofovir/emtricitabine 
(RAL+TDF/FTC). Adherence is critical to the success of ART in suppressing viral 
load and avoiding virological failure and development of drug resistance. This 
study compared ART adherence between preferred ART regimens in a real-world 
setting. METHODS: Retrospective study using U.S. Medicaid administrative 
health care claims from 15 states. Subjects were HIV patients aged 18-64 years 
who were enrolled in Medicaid and initiated, between January 1, 2007 and 
September 30, 2011, a first-line ART regimen “preferred” under U.S. DHHS HIV 
treatment guidelines published in March 2012. Patients were classified by ART 
regimen and were required to 4be continuously enrolled for 6 months before and 
≥3 months following ART initiation. Follow up lasted from ART initiation until a 
≥30 day gap in initiated ART, introduction of a new ART medication, or 
disenrollment. Adherence, defined as the proportion of days covered by ART 
medication during follow up (dichotomized at ≥80%), was evaluated using 
multivariable logistic regressions that adjusted for demographic and clinical 
factors. RESULTS: Sample included 1,979 patients initiating EFV/TDF/FTC 
(n=1,259), ATV/r+TDF/FTC (n=498), DRV/r+TDF/FTC (n=143), or RAL+TDF/FTC 
(n=79); mean age by regimen ranged from 40.1 to 42.1 years and proportion male 
from 44.1% to 55.4%. Compared with patients initiating EFV/TDF/FTC, odds of 
adherence ≥80% were significantly lower in DRV/r+TDF/FTC patients (odds ratio 
[OR]=0.56, p=0.045) and trended lower in RAL+TDF/FTC patients (OR=0.666, 
p=0.273) and ATV/r+TDF/FTC patients (OR=0.904, p=0.610). CONCLUSIONS: 
Among patients initiating a DHHS guideline-preferred first-line ART regimen, the 
odds of adherence were not the same for all regimens. Further research should 
explore the reasons for differences in adherence levels between “preferred” ART 
regimens.  
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OBJECTIVES: The study evaluated medication adherence and its association with 
CD4 cells response following interventions among patients receiving 
antiretroviral therapy (ART) in Specialist Hospital Sokoto, North Western Nigeria 
METHODS: This was cross-sectional study following adherence interventions 
that included training of health workers on cognitive and behavioural strategies 
for improving medication adherence; and a pre- and post-ART adherence 
counseling to patients. Out of 1300 patients on ART who were provided pre- and 
post-ART adherence counseling, announced pill counts were conducted in 365 
randomly selected patients. The CD4 cell count (cells/mm3) at months 0, 6, 12, 18 
and 24 were extracted from the patient’s records. One-way Anova was used to 
test the association between groups of variables and p<0.05 indicated statistical 
significance. RESULTS: Out of 365 participants sampled, data from 297 (81.4%) of 
them were valid for analysis. The mean age of participants was 34.7 (95%CI, 33.6–
35.8) years; 60.9% were females and 76.4% received an AZT/3TC/NVP regimen. 
The mean percent adherence was 83.4% (95%CI, 80.8–86.0); and 52.2% reported 
100% adherence level. With this mean adherence level, the mean CD4-cell count 
(cells/mm3) at ART initiation increased from 198.9 (95%CI, 180.7–217.1) to 396.5 
(95%CI, 368.3–24.7) at 6 months, 428.0 (95%CI, 400.4–455.6) at 12 months, 427.2 
(95%CI, 405.6–448.8) at 18 months, and 501.4 (95%CI, 469.5–533.3) at 24 months. 
This increase was statistically significant (p<0.05). The participants’ employment 
and educational status, age, sex and type of ART regimens received had no 
significant association with medication adherence (p>0.05). CONCLUSIONS: The 
study reported mean adherence level that is below the required >95% necessary 
to achieve the goals of ART. The increase in CD4 cells count over the observation 
period was statistically significant at the reported adherence level. Better 
immunologic outcomes may be achieved with higher adherence level.  
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OBJECTIVES: To determine if the SF-12 survey (using the PCS and MCS) can 
discriminate between predefined HIV severity states (as defined by CD4 and viral 
load) in a Kenyan population. The discriminative ability of the SF-12 quality of 
life instrument has been tested in patients with HIV/AIDS. In a US study, 
patients were stratified by CD4 count and viral load as a threshold for severity of 
disease. Associations between severity and mental component score 
(MCS)/physical component score (PCS) were investigated. The study found an 
association between CD4 threshold and PCS score. Using similar methods, we 
tested the same hypotheses using a Swahili translation of the SF-12 in a Kenyan 
population of HIV positive patients. METHODS: This cross-sectional study was 
based on data from a randomized controlled trial conducted in Nairobi, Kenya 
involving HIV patients. CD4 count, viral load, and SF-12 survey results were 
collected on patients initiating anti-retroviral therapy at 3 clinics. Clinical 
variables were stratified as follows: CD4≥200 cells/mm3compared to CD4<200 and 
viral load>55000 copies/mL compared to viral load ≤55000. The PCS and MCS 
scores means were compared across these strata using a t test. RESULTS: CD4 
counts were measured in 280 patients and viral load in 497 patients. All patients 
completed the SF-12 instrument. PCS scores showed significant discriminative 
ability in the CD4 comparison (p<0.01) with a mean(SD) of 41.3(11.42) for CD4<200 
cells/mm3compared to 45.1(11.2) for CD4≥200. Comparison in viral load strata 
and MCS scores were not significant. Mean and standard deviation for both MCS 
and PCS in each severity state were similar in value to those reported in the 
earlier American trial. CONCLUSIONS: These findings suggest that a Swahili 
translation of the SF-12 is a useful instrument in discriminating across limited 
clinical variables of HIV disease progression and severity.  
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OBJECTIVES: Physician’s perception regarding parents’ expectation to receive 
antibiotic prescription for their children is a significant predictor of 
overprescribing antibiotics for young children in the United States. The objective 
was to evaluate whether parents’ level of expectation would change after 
manipulating their ‘perceived benefits of using antibiotics’ and their ‘perceived 
barriers to visit doctors without any expectation of antibiotic prescription’. 
METHODS: A prospective experimental study was conducted using a structured 
data-collection instrument to manipulate perceived barriers and perceived 
benefits using four scenarios and keep other factors of Health Belief Model 
constant. Each subject viewed four scenarios; expectation associated with each 
scenario was measured using visual-analog-scale. Data were collected at public 
places (Houston,TX) from subjects who had at least one child (age≤5 years) 
during the study and who could speak, read and write English. Psychometric 
properties of the instrument were tested; descriptive and repeated measures 
mixed method covariance adjusted analyses were performed using SAS®9.3 with 
0.05 significance level. RESULTS: A total of 300 completed surveys were 
analyzed. Mean age of the sample was 30.3±7 years. The mean general 
expectation score (before reading any scenario) to receive antibiotic prescription 
for children was 53.6±25.7. The repeated measure mixed methods analyses 
indicated that there was 12-point reduction (p<0.0001) in expectation score after 
removing perceived barriers from the situational scenarios; 16-point decrease 
(p<0.0001) in expectation score was observed after removing perceived benefits 
and 18-point decrease (p<0.0001) in expectation score after removing both 
perceived barriers and perceived benefits. CONCLUSIONS: There was significant 
effect of perceived barriers and perceived benefits on expectation scores. When 
both perceived barriers and perceived benefits were removed from the scenarios 
there was the highest decrease in the expectation score indicating the successful 
manipulation of both variables. Policy makers and intervention programs should 
consider these factors to enhance successful reduction of antibiotic expectations.  
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OBJECTIVES: Vaccination rates for influenza and pneumococcal disease do not 
meet established goals in older minority populations. This project assessed 
potential reasons for this through a survey of community-dwelling African 
American seniors. METHODS: A 23-question survey was developed and fielded to 
a group of participants at a Philadelphia community senior center. Survey 
content was informed by previously-tested instruments in the literature and 
consisted of 18 Likert-scale items assessing potential barriers to pneumonia 
vaccine (PV) and influenza vaccine (IV); yes/no questions assessing awareness of 
PV and IV; and open-ended questions gathering opinions supporting and 
opposing these vaccines. RESULTS: A total of participants completed the survey. 
Awareness of PV was slightly lower than IV (36/39 vs. 39/39; p=.077) but there 
were no differences in perceived importance of PV versus IV. Most (91.9%) agreed 
that both vaccines are important to their health, but more than half (52.6%) felt 
that these vaccines can cause illness. Only a third (34.3%) believed that vaccines 
protect against pneumonia and influenza. Many participants (65.6%) indicated 
fear as a barrier to vaccination, with most of these (35.1%) specifying fear of 
illness or adverse reaction, 16.2% fear of needles, and 16.2% reporting other fears. 
While most trusted pharmacists as an information source for vaccination 
(75.7%), less than half (44.4%) are comfortable getting vaccines from pharmacists. 
CONCLUSIONS: This is the first survey to identify PV and IV barriers among 
African Americans through a community senior center. Though awareness of 
both vaccines is high, fear of vaccination is common and represents a significant 
barrier, as does the notion that these vaccines cause illness. Pharmacists are a 
trusted information source regarding vaccines but are not yet established as 
trusted vaccine providers in this population. Results serve to inform outcomes 
researchers’ efforts to design and evaluate vaccination programs targeted 
towards African American seniors.  
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